(Approval lapsed 6/01/2020) Intuniv 1mg Extended Release tablets
Section 19A approved medicine
(Approval lapsed 6/01/2020) Intuniv 1mg Extended Release tablets
Section 19A approval holder
Shire Australia Pty Ltd
Phone
02 8019 4400
Approved until
Status
Lapsed
Medicines in short supply/unavailable
Intuniv (guanfacine hydrochloride) 1mg - ARTG 275278
Indication(s)
INTUNIV is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). INTUNIV must be used as part of a comprehensive ADHD management programme, typically including psychological, educational and social measures.